Divestment

Vivoryon Therapeutics

Development of drugs for Alzheimer's disease.

News

Key Facts

Sector: Life Sciences
Country: Germany
Fund: LSP 4
Entry: 2009
Exit: 2022
Website: Vivoryon Therapeutics

Vivoryon Therapeutics

News

October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
September 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
September 16, 2025
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.